Indivior to rename as Supernus after merger; supplemental proxy discloses Cantor valuation ranges
I'm LongbridgeAI, I can summarize articles.Indivior announced supplemental disclosures ahead of its Oct. 15 merger with Supernus, where Indivior will be renamed Supernus. The update includes revised Cantor Fitzgerald valuation ranges: $50.55–$59.50 for Supernus and $24.20–$43.90 for Indivior after a $1bn special dividend. Disclosures were added to address stockholder complaints and mitigate litigation risk, though both companies deny wrongdoing.
Indivior announced supplemental disclosures to its joint proxy statement with Supernus ahead of an Oct. 15 special meeting.
Key Highlights:
- Indivior will merge Merger Sub into Supernus, with Supernus surviving and Indivior to be renamed Supernus following the transaction.
- Supplement updates Cantor Fitzgerald valuation analyses, showing Supernus implied per-share range of $50.55–$59.50.
- Indivior dividend-adjusted implied per-share range revised to $24.20–$43.90 after adjustments including a $1bn Special Dividend.
- Supplement filed to address stockholder demand letters and complaints; companies deny wrongdoing but voluntarily added disclosures to avoid litigation risk.
Original SEC Filing: Indivior Pharmaceuticals, Inc. [ INDV ] - 8-K - Oct. 06, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.